LifeMD Securities Case Reaches Lead-Plaintiff Deadline as Firms Court Investors

Overview

• Investors who bought LifeMD shares between May 7 and August 5, 2025 face an October 27 deadline to seek lead-plaintiff status in the Eastern District of New York case, Johnston v. LifeMD.
• Rosen Law Firm filed the action, and Faruqi & Faruqi, Bragar Eagel & Squire, Hagens Berman, and DJS Law Group are urging investors to contact them, including potential whistleblowers.
• The complaint alleges LifeMD overstated its competitive position and raised 2025 guidance without disclosing rising RexMD customer acquisition costs and higher refund rates tied to weight-loss offerings, including exposure to drugs such as Wegovy and Zepbound.
• The suit centers on LifeMD’s August 5, 2025 second-quarter results and guidance cut—revenue outlook to $250–$255 million from $268–$275 million—after which the stock fell about 44.8% on August 6.
• No class has been certified, investors are not represented unless they retain counsel or a class is certified, and the appointed lead plaintiff will direct the litigation under the PSLRA framework.